11.30 USD
▼-0.26-2.25%
盘后 11.27 -0.27%
2026-09-15
市值
$996.36M
市盈率
—
EPS
-3.36
股息率
—
52 周区间
7.36 – 13.90
成交量
1.83M
Beta
0.43
目标价
32.00
52W 低 7.3652W 高 13.90
价格走势
公司简介
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n...